Do you want to read an article? Please log in or register.
Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Related content
Cardiovascular Risk and Diseases
Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial
JAMA Cardiol.
Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA
doi: 10.1001/jamacardio.2019.3080.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy
J Am Heart Assoc.
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE
doi: 10.1161/JAHA.119.014328.
Cardiovascular Risk and Diseases
Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials
Eur Heart J.
Marsico F, Paolillo S, Gargiulo P, Bruzzese D, Dell'Aversana S, Esposito I, Renga F, Esposito L, Marciano C, Dellegrottaglie S, Iesu I, Perrone Filardi P
doi: 10.1093/eurheartj/ehaa082.
RECOMMENDED
Cardiovascular Risk and DiseasesMyocardial InfarctionThrombosis and Stroke
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial
Lancet.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, Howard G, Pearson TA, Rothwell PM, Ruilope LM, Tendera M, Tognoni G, ARRIVE Executive Committee
doi: 10.1016/S0140-
RECOMMENDED
Cardiovascular Risk and Diseases
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Arnott C, Li Q, Kang A, Neuen BL, Bompoint S, Lam CSP, Rodgers A, Mahaffey KW, Cannon CP, Perkovic V, Jardine MJ, Neal B
doi: 10.1161/JAHA.119.014908.
Cardiovascular Risk and DiseasesHypertension
Blood pressure variability and risk of cardiovascular events and death in patients with hypertension and different baseline risks
Eur Heart J.
Mehlum MH, Liestøl K, Kjeldsen SE, Julius S, Hua TA, Rothwell PM, Mancia G, Parati G, Weber MA, Berge E
doi: 10.1093/
Cardiovascular Risk and DiseasesThrombosis and Stroke
Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus
Circulation
Capodanno D, Angiolillo DJ
doi: 10.1161/CIRCULATIONAHA.120.045465
RECOMMENDED
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
doi: 10.1016/S0140-
COMMENTED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHeart Failure
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Circulation
Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo Jack S, Frederich R, Charbonnel B, Mancuso J, Shih WJ, Terra SG, Cater NB, Gantz I, McGuire DK, VERTIS CV Investigators.
doi: 10.1161/CIRCULATIONAHA.120.050255